Clinical Expert Panel session at the 2022 ASF Family Conference
Join the Clinical Expert Panel at the 2022 ASF Family Conference for insights on managing Angelman syndrome. Learn about common medical issue
Behavior and Anxiety in AS
Explore the common behavioral issues and anxiety in individuals with Angelman Syndrome. Learn about their frequency, severity, causes, and effective strategies for management and intervention.
Stepping Into AAC. Family supports for enhancing communication
Explore the Stepping into AAC project, a collaboration between the Angelman Syndrome Foundation and PrAACtical AAC, providing resources to enhance family’s AAC journeys.
Planning with Mary Anne Ehlert
Join Mary Anne Elhert at the 2023 ASF Virtual Conference as she shares valuable insights on disability planning. Learn about Protected Tomorrow’s mission, services, and upcoming classes. Your guide to a secure future.
Behavior and Anxiety in Angelman Syndrome
Explore effective strategies to manage behavior problems and anxiety in Angelman syndrome. Learn about behavioral and medical interventions, and participate in our research.
Adult Care in Angelman Syndrome
Explore comprehensive adult care for Angelman Syndrome with Jessica Duis, Director of the Angelman Syndrome Clinic. Learn about transition programs, guardianship, long-term planning, nutritional and behavioral changes, and more.
Abnormal Movements in AS
Explore Dr. Robert Carson’s insights on understanding and managing abnormal movements in Angelman Syndrome. Learn about non-epileptic myoclonus and future research plans.
ASF Center of Excellence
Explore the Angelman Syndrome Foundation Center of Excellence, offering comprehensive care, education, and support for individuals with Angelman Syndrome. Reach out for help today!
2023 Ultragenyx Update
Join the 2023 ASF Virtual Conference to learn about Ultragenyx’s latest developments in rare disease treatments, including the GTX-102 program for Angelman syndrome.
2023 Neuren Pharmaceuticals Update
Explore Neuren Pharmaceuticals’ latest updates on their clinical development program for Angelman Syndrome, including progress on Trofinetide and NNZ-2591 treatments.